Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: GlobalData
$250.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Omeros Corporation announces positive OMS721 Data in Serum from patients with aHUS


Monday, 10 Mar 2014 07:00am EDT 

Omeros Corporation:Positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program.Thrombotic microangiopathy (TMA) are a family of rare, debilitating and life-threatening disorders characterized by multiple thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain.Phase 2 clinical trial in aHUS and other TMAs expected to begin next quarter. 

Company Quote

14.16
-0.19 -1.32%
10:32am EDT